# Programmed Death-1(PD-1) Inhibitor Combined With Progesterone Treatment in Endometrial Cancer

> **NCT04046185** · EARLY_PHASE1 · UNKNOWN · sponsor: **Shanghai First Maternity and Infant Hospital** · enrollment: 60 (estimated)

## Conditions studied

- Endometrial Cancer Stage I

## Interventions

- **DRUG:** PD-1 inhibitor combined progesterone
- **DRUG:** progesterone

## Key facts

- **NCT ID:** NCT04046185
- **Lead sponsor:** Shanghai First Maternity and Infant Hospital
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-10-01
- **Primary completion:** 2021-10-01
- **Final completion:** 2022-10-01
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2019-08-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04046185

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04046185, "Programmed Death-1(PD-1) Inhibitor Combined With Progesterone Treatment in Endometrial Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04046185. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*